Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

阿尔茨海默病中的脑脊液炎症标志物：合并症的影响

卷 18, 期 2, 2021

发表于: 30 March, 2021

页: [157 - 170] 页: 14

弟呕挨: 10.2174/1567205018666210330162207

open access plus

摘要

背景：阿尔茨海默病（AD）在几年后发展为痴呆，主观认知障碍（SCI）和轻度认知障碍（MCI）被用作日益严重的中间诊断。炎症是 AD 病理学的重要组成部分，并提供潜在的新型生物标志物和治疗目标。 目的：鉴定脑脊液 (CSF) 中 AD 的新型潜在生物标志物，并创建炎症因子的分子模式，以区分 AD 和 SCI。 方法：我们分析了 SCI 和 AD 病例队列（训练队列）中 CSF 样本中的 43 种炎症相关介质。使用多变量分析 (MVA)，产生了一个区分 SCI 和 AD 的模型，然后我们将其应用于更大的未经审查的队列（称为测试队列）。数据分析了显示诊断组之间差异的因素以及经过审查和未经审查的队列之间存在差异的因素。研究了这些因素与模型和临床诊断之间的一致性的关系。 结果：从训练队列中产生了一个良好的 MVA 模型，能够在不包括缠结和斑块生物标志物的情况下将 AD 与 SCI 区分开来。该模型与测试队列中的临床诊断有 50% 的一致性。队列的比较表明区分 SCI 和 AD 的因素的不同模式。例如，可溶性白细胞介素 (IL)-6Rα 在训练组的 AD 病例中显示出较低的水平，而在测试组的 AD 病例中，胎盘生长因子 (PlGF) 和血清淀粉样蛋白 A (SAA) 的水平较高。训练组的 p-tau 水平也更高。 结论：本研究通过根据是否存在潜在的混杂合并症来指示 CSF 中的不同因素模式，提供了关于炎症在 AD 中的参与的新知识，并提出 sIL-6Rα 作为改进 AD 诊断的潜在新生物标志物。

关键词: 阿尔茨海默病、生物标志物、脑脊液、诊断、炎症、多变量分析。

« Previous Next »
[1]
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018 ] [PMID: 29653606]
[2]
Reisberg B, Prichep L, Mosconi L, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimers Dement 2008; 4(1): S98-S108.
[http://dx.doi.org/10.1016/j.jalz.2007.11.017 ] [PMID: 18632010]
[3]
Goedert M, Masuda-Suzukake M, Falcon B. Like prions: The propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 2017; 140(2): 266-78.
[http://dx.doi.org/10.1093/brain/aww230 ] [PMID: 27658420]
[4]
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol 2016; 15(7): 673-84.
[http://dx.doi.org/10.1016/S1474-4422(16)00070-3 ] [PMID: 27068280]
[5]
Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A β deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55(10): 1083-8.
[http://dx.doi.org/10.1097/00005072-199655100-00008 ] [PMID: 8858005]
[6]
Knopman DS, Haeberlein SB, Carrillo MC, et al. The national institute on aging and the Alzheimer’s association research framework for Alzheimer’s disease: Perspectives from the research roundtable. Alzheimers Dement 2018; 14(4): 563-75.
[http://dx.doi.org/10.1016/j.jalz.2018.03.002 ] [PMID: 29653607]
[7]
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14(4): 388-405.
[http://dx.doi.org/10.1016/S1474-4422(15)70016-5 ] [PMID: 25792098]
[8]
Kobro-Flatmoen A, Lagartos-Donate MJ, Aman Y, Edison P, Witter MP, Fang EF. Re-emphasizing early Alzheimer’s disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. Ageing Res Rev 2021; 67101307
[http://dx.doi.org/10.1016/j.arr.2021.101307 ] [PMID: 33621703]
[9]
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci 2019; 22(3): 401-12.
[http://dx.doi.org/10.1038/s41593-018-0332-9 ] [PMID: 30742114]
[10]
Kuehn BM. In Alzheimer research, glucose metabolism moves to center stage. JAMA 2020; 323(4): 297-9.
[http://dx.doi.org/10.1001/jama.2019.20939 ] [PMID: 31913419]
[11]
Janota C, Lemere CA, Brito MA. Dissecting the contribution of vascular alterations and aging to Alzheimer’s disease. Mol Neurobiol 2016; 53(6): 3793-811.
[http://dx.doi.org/10.1007/s12035-015-9319-7 ] [PMID: 26143259]
[12]
Hamelin L, Lagarde J, Dorothée G, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain 2018; 141(6): 1855-70.
[http://dx.doi.org/10.1093/brain/awy079 ] [PMID: 29608645]
[13]
Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Front Immunol 2018; 9: 2122.
[http://dx.doi.org/10.3389/fimmu.2018.02122 ] [PMID: 30283455]
[14]
Cacabelos R, Barquero M, García P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1 β (IL-1 β) in Alzheimer’s disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991; 13(7): 455-8.
[PMID: 1784142]
[15]
Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86(19): 7611-5.
[http://dx.doi.org/10.1073/pnas.86.19.7611 ] [PMID: 2529544]
[16]
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-98.
[http://dx.doi.org/10.1016/0022-3956(75)90026-6 ] [PMID: 1202204]
[17]
Naik M, Nygaard HA. Diagnosing dementia -- ICD-10 not so bad after all: A comparison between dementia criteria according to DSM-IV and ICD-10. Int J Geriatr Psychiatry 2008; 23(3): 279-82.
[http://dx.doi.org/10.1002/gps.1874 ] [PMID: 17702050]
[18]
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256(3): 240-6.
[http://dx.doi.org/10.1111/j.1365-2796.2004.01380.x ] [PMID: 15324367]
[19]
Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. Int Psychogeriatr 2008; 20(1): 1-16.
[http://dx.doi.org/10.1017/S1041610207006412 ] [PMID: 18072981]
[20]
Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23(2): 312-28.
[http://dx.doi.org/10.1007/s11095-005-9045-3 ] [PMID: 16397743]
[21]
McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995; 21(2): 195-218.
[http://dx.doi.org/10.1016/0165-0173(95)00011-9 ] [PMID: 8866675]
[22]
El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to β-amyloid. J Exp Med 2003; 197(12): 1657-66.
[http://dx.doi.org/10.1084/jem.20021546 ] [PMID: 12796468]
[23]
Ban E, Milon G, Prudhomme N, Fillion G, Haour F. Receptors for interleukin-1 (α and β) in mouse brain: Mapping and neuronal localization in hippocampus. Neuroscience 1991; 43(1): 21-30.
[http://dx.doi.org/10.1016/0306-4522(91)90412-H ] [PMID: 1833666]
[24]
Maphis N, Xu G, Kokiko-Cochran ON, et al. Loss of tau rescues inflammation-mediated neurodegeneration. Front Neurosci 2015; 9: 196.
[http://dx.doi.org/10.3389/fnins.2015.00196 ] [PMID: 26089772]
[25]
Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23(5): 1605-11.
[http://dx.doi.org/10.1523/JNEUROSCI.23-05-01605.2003 ] [PMID: 12629164]
[26]
Lee YJ, Kim JE, Kwak MH, et al. Selenium treatment significantly inhibits tumor necrosis factor-α-induced cell death and tau hyperphosphorylation in neuroblastoma cells. Mol Med Rep 2014; 10(4): 1869-74.
[http://dx.doi.org/10.3892/mmr.2014.2442 ] [PMID: 25109896]
[27]
Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci 2014; 15(4): 209-16.
[http://dx.doi.org/10.1038/nrn3710 ] [PMID: 24646669]
[28]
Rajendran L, Paolicelli RC. Microglia-mediated synapse loss in Alzheimer’s disease. J Neurosci 2018; 38(12): 2911-9.
[http://dx.doi.org/10.1523/JNEUROSCI.1136-17.2017 ] [PMID: 29563239]
[29]
Cumiskey D, Pickering M, O’Connor JJ. Interleukin-18 mediated inhibition of LTP in the rat dentate gyrus is attenuated in the presence of mGluR antagonists. Neurosci Lett 2007; 412(3): 206-10.
[http://dx.doi.org/10.1016/j.neulet.2006.11.007 ] [PMID: 17123727]
[30]
Lynch MA. Neuroinflammatory changes negatively impact on LTP: A focus on IL-1β. Brain Res 2015; 1621: 197-204.
[http://dx.doi.org/10.1016/j.brainres.2014.08.040]
[31]
Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011; 25(2): 181-213.
[http://dx.doi.org/10.1016/j.bbi.2010.10.015 ] [PMID: 20970492]
[32]
Llano DA, Devanarayan V, Simon AJ. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2013; 27(3): 233-43.
[http://dx.doi.org/10.1097/WAD.0b013e31826d597a ] [PMID: 23023094]
[33]
Wang T, Wang BR, Zhao HZ, et al. Lipopolysaccharide up-regulates IL-6R α expression in cultured leptomeningeal cells via activation of ERK1/2 pathway. Neurochem Res 2008; 33(9): 1901-10.
[http://dx.doi.org/10.1007/s11064-008-9667-z ] [PMID: 18357518]
[34]
Birner P, Heider S, Petzelbauer P, et al. Interleukin-6 receptor α blockade improves skin lesions in a murine model of systemic lupus erythematosus. Exp Dermatol 2016; 25(4): 305-10.
[http://dx.doi.org/10.1111/exd.12934 ] [PMID: 26739431]
[35]
Ito Y, Yamamoto M, Li M, et al. Differential temporal expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR α, LIFR β, IL-6R α and gp130) in injured peripheral nerves. Brain Res 1998; 793(1-2): 321-7.
[http://dx.doi.org/10.1016/S0006-8993(98)00242-X ] [PMID: 9630704]
[36]
Baran P, Hansen S, Waetzig GH, et al. The balance of interleukin (IL)-6, IL-6•soluble IL-6 receptor (sIL-6R), and IL-6•sIL-6R•sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem 2018; 293(18): 6762-75.
[http://dx.doi.org/10.1074/jbc.RA117.001163 ] [PMID: 29559558]
[37]
Rose-John S. The soluble interleukin 6 receptor: Advanced therapeutic options in inflammation. Clin Pharmacol Ther 2017; 102(4): 591-8.
[http://dx.doi.org/10.1002/cpt.782 ] [PMID: 28675418]
[38]
Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010; 35(13): 2617-23.
[http://dx.doi.org/10.1038/npp.2010.159 ] [PMID: 20881945]
[39]
Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci 2020; 21(6): 2194.
[http://dx.doi.org/10.3390/ijms21062194 ] [PMID: 32235786]
[40]
Newton TL, Fernandez-Botran R, Miller JJ, Burns VE. Interleukin-6 and soluble interleukin-6 receptor levels in posttraumatic stress disorder: Associations with lifetime diagnostic status and psychological context. Biol Psychol 2014; 99: 150-9.
[http://dx.doi.org/10.1016/j.biopsycho.2014.03.009 ] [PMID: 24695006]
[41]
Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999; 45(7): 833-9.
[http://dx.doi.org/10.1016/S0006-3223(98)00131-0 ] [PMID: 10202570]
[42]
Clausen BH, Lambertsen KL, Dagnæs-Hansen F, et al. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol 2016; 131(5): 775-91.
[http://dx.doi.org/10.1007/s00401-016-1541-5 ] [PMID: 26860727]
[43]
Oprica M, Hjorth E, Spulber S, et al. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med 2007; 11(4): 810-25.
[http://dx.doi.org/10.1111/j.1582-4934.2007.00074.x ] [PMID: 17760842]
[44]
Spulber S, Mateos L, Oprica M, et al. Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL-1ra in the brain. J Neuroimmunol 2009; 208(1-2): 46-53.
[http://dx.doi.org/10.1016/j.jneuroim.2009.01.010 ] [PMID: 19211154]
[45]
Tarkowski E, Liljeroth AM, Nilsson A, Minthon L, Blennow K. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001; 12(5): 314-7.
[http://dx.doi.org/10.1159/000051276 ] [PMID: 11455132]
[46]
Taipa R. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol Aging 2019; 76: 125-32.
[47]
Janelidze S, Mattsson N, Stomrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 2018; 91(9): e867-77.
[http://dx.doi.org/10.1212/WNL.0000000000006082 ] [PMID: 30054439]
[48]
Li M, Li Z, Yao Y, et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci USA 2017; 114(3): E396-405.
[http://dx.doi.org/10.1073/pnas.1612930114 ] [PMID: 27994144]
[49]
Wang X, Zhu M, Hjorth E, et al. Resolution of inflammation is altered in Alzheimer's disease 2015.
[50]
Zhou Z, Peng X, Insolera R, Fink DJ, Mata M. IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol 2009; 220(1): 183-90.
[http://dx.doi.org/10.1016/j.expneurol.2009.08.018 ] [PMID: 19716366]
[51]
Gao Y, Tu D, Yang R, Chu CH, Hong JS, Gao HM. Through reducing ROS production, IL-10 suppresses caspase-1-dependent IL-1β maturation, thereby preventing chronic neuroinflammation and neurodegeneration. Int J Mol Sci 2020; 21(2): 465.
[http://dx.doi.org/10.3390/ijms21020465 ] [PMID: 31940754]
[52]
Fouda AY, Pillai B, Dhandapani KM, Ergul A, Fagan SC. Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury. Eur J Pharmacol 2017; 799: 128-34.
[http://dx.doi.org/10.1016/j.ejphar.2017.02.016 ] [PMID: 28192099]
[53]
Ryu JK, Cho T, Choi HB, Jantaratnotai N, McLarnon JG. Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease. J Neuroinflammation 2015; 12: 144.
[http://dx.doi.org/10.1186/s12974-015-0339-z ] [PMID: 26255110]
[54]
Chakrabarty P, Ceballos-Diaz C, Beccard A, et al. IFN-γ promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 2010; 184(9): 5333-43.
[http://dx.doi.org/10.4049/jimmunol.0903382 ] [PMID: 20368278]
[55]
Monsonego A, Imitola J, Petrovic S, et al. Abeta-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2006; 103(13): 5048-53.
[http://dx.doi.org/10.1073/pnas.0506209103 ] [PMID: 16549802]
[56]
Monteiro S, Ferreira FM, Pinto V, et al. Absence of IFNγ promotes hippocampal plasticity and enhances cognitive performance. Transl Psychiatry 2016; 6e707
[http://dx.doi.org/10.1038/tp.2015.194]
[57]
Zhang J, He H, Qiao Y, et al. Priming of microglia with IFN-γ impairs adult hippocampal neurogenesis and leads to depression-like behaviors and cognitive defects. Glia 2020; 68(12): 2674-92.
[http://dx.doi.org/10.1002/glia.23878 ] [PMID: 32652855]
[58]
Liu J, Gao L, Zang D. Elevated levels of IFN-γ in CSF and serum of patients with amyotrophic lateral sclerosis. PLoS One 2015; 10(9)e0136937
[http://dx.doi.org/10.1371/journal.pone.0136937 ] [PMID: 26332465]
[59]
Cao X, Chen P. Changes in serum amyloid A (SAA) and 8-OHdG in patients with senile early cognitive impairment. Med Sci Monit 2020; 26e919586
[60]
Sack GH Jr. Serum amyloid A - a review. Mol Med 2018; 24(1): 46.
[http://dx.doi.org/10.1186/s10020-018-0047-0 ] [PMID: 30165816]
[61]
O’Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000; 2(2): 142-4.
[http://dx.doi.org/10.1186/ar78 ] [PMID: 11062604]
[62]
Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through toll-like receptor-2. Am J Respir Crit Care Med 2010; 181(4): 360-73.
[http://dx.doi.org/10.1164/rccm.200905-0696OC ] [PMID: 19910611]
[63]
Brosseron F, Traschütz A, Widmann CN, et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res Ther 2018; 10(1): 25.
[http://dx.doi.org/10.1186/s13195-018-0353-3 ] [PMID: 29482610]
[64]
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.
[http://dx.doi.org/10.1038/nature10144 ] [PMID: 21593862]
[65]
Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 2020; 16(1): 30-42.
[http://dx.doi.org/10.1038/s41582-019-0281-2 ] [PMID: 31827267]
[66]
Biron KE, Dickstein DL, Gopaul R, Jefferies WA, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer’s disease. PLoS One 2011; 6(8)e23789
[http://dx.doi.org/10.1371/journal.pone.0023789 ] [PMID: 21909359]
[67]
Du H, Li P, Pan Y, et al. Vascular endothelial growth factor signaling implicated in neuroprotective effects of placental growth factor in an in vitro ischemic model. Brain Res 2010; 1357: 1-8.
[http://dx.doi.org/10.1016/j.brainres.2010.07.015 ] [PMID: 20637183]
[68]
Liu H, Honmou O, Harada K, et al. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006; 129(Pt 10): 2734-45.
[http://dx.doi.org/10.1093/brain/awl207 ] [PMID: 16901914]
[69]
Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005; 111(21): 2828-36.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.495887 ] [PMID: 15911697]
[70]
Sainz J, Sata M. Is PlGF a plaque growth factor? Cardiovasc Res 2010; 86(1): 4-5.
[http://dx.doi.org/10.1093/cvr/cvq037 ] [PMID: 20123695]
[71]
Yoo SA, Yoon HJ, Kim HS, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: A link between angiogenesis and inflammation. Arthritis Rheum 2009; 60(2): 345-54.
[http://dx.doi.org/10.1002/art.24289 ] [PMID: 19180491]
[72]
Saccenti E, Timmerman ME. Approaches to sample size determination for multivariate data: Applications to PCA and PLS-DA of omics data. J Proteome Res 2016; 15(8): 2379-93.
[http://dx.doi.org/10.1021/acs.jproteome.5b01029 ] [PMID: 27322847]
[73]
Pang Z, Wang G, Wang C, Zhang W, Liu J, Wang F. Serum metabolomics analysis of asthma in different inflammatory phenotypes: A cross-sectional study in Northeast China. BioMed Res Int 2018; 20182860521
[http://dx.doi.org/10.1155/2018/2860521 ] [PMID: 30345296]
[74]
Sjöbom U, Christenson K, Hellström A, Nilsson AK. Inflammatory markers in suction blister fluid: A comparative study between interstitial fluid and plasma. Front Immunol 2020; 11597632
[http://dx.doi.org/10.3389/fimmu.2020.597632 ] [PMID: 33224151]
[75]
Probert F, Walsh A, Jagielowicz M, et al. Plasma nuclear magnetic resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis. J Crohn’s Colitis 2018; 12(11): 1326-37.
[http://dx.doi.org/10.1093/ecco-jcc/jjy101 ] [PMID: 30016408]
[76]
Peng Y, Ren H, Tao H, et al. Metabolomics study of the anti-inflammatory effects of endogenous ω-3 polyunsaturated fatty acids. RSC Advances 2019; 9(71): 41903-12.
[http://dx.doi.org/10.1039/C9RA08356A]
[77]
Ma H, Hong M, Duan J, et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: A case-control study. PLoS One 2013; 8(2)e55200
[http://dx.doi.org/10.1371/journal.pone.0055200 ] [PMID: 23390521]

Rights & Permissions Print Cite
Article Metrics
104
6
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy